Bayer's Asundexian Green Light Comes With a Jefferies Price Tag Below the Market
Published on 11/13/2026 at 19:42 | Editorial boerse-global.de
Bayer shares pushed to a fresh 52-week high on Tuesday, yet the stock is trading well above the level at which Jefferies is willing to recommend it. The US approval of Asundexian — marketed as Sunharbo — removes a substantial cloud over the company's pharmaceutical pipeline, but the broker kept its "Hold" rating and a price target of EUR 48.50 even as the equity changed hands at EUR 56.46.
Analyst Michael Leuchten framed the FDA decision as a de-risking event rather than a re-rating trigger. The clearance covers adults who have suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack, and the drug is to be used alongside antiplatelet therapy. According to Bayer, Asundexian is the first Factor XIa inhibitor ever approved anywhere in the world, with the Phase III OCEANIC-STROKE trial underpinning the regulator's verdict.
A Second Approval and a Full Pipeline
The stroke drug is not the only regulatory win the group has banked. On 4 November, Bayer secured a green light in China for Sevabertinib as a first-line treatment for adults with unresectable, locally advanced or metastatic non-small cell lung cancer carrying activating HER2 mutations.
Behind those headline approvals sits a third-quarter update that gave the market plenty to chew on. Bayer reported group revenue of EUR 10.1 billion for Q3 2026 and EBITDA before special items of EUR 1.62 billion, with both the top line and the adjusted operating result moving higher year on year, according to company figures.
Should investors sell immediately? Or is it worth buying Bayer?
Management used the quarterly statement to lift its full-year guidance on several fronts: the margin of the pharmaceuticals division, group EBITDA before special items, and free cash flow. Bayer also flagged a lower net financial debt position at year-end than previously expected.
India Plant, US Herbicide and a Consumer Health Push
Alongside the pharma newsflow, the company has been busy on the industrial and agricultural side. On 6 November it signed a memorandum of understanding with the government of Karnataka, with media reports putting the planned investment at 200 crore rupees for a new production site near Bengaluru, spread across seven years. The agreement covers an intended project; the sums are to be deployed over that period.
The same day brought word that Bayer had completed the first shipment of its Convintro herbicide in the United States, a product earmarked for the 2027 growing season. Bayer Consumer Health, meanwhile, has reportedly sealed four strategic cooperation agreements, with Sirio Pharma, Jointown Pharmaceutical Group, Ruoyuchen and Shanghai Pharma Holding named as partners.
Bayer at a turning point? This analysis reveals what investors need to know now.
Roundup Litigation Turns a Corner
There was legal news too. According to Bayer, Monsanto won the first Roundup case to go to trial since the US Supreme Court's ruling, with the verdict delivered unanimously on 30 October.
The shares were up 0.4% at EUR 56.76 in the latest session, extending a run that has gathered pace on the back of the recent announcements. For all the momentum, the gap between the market price and Jefferies' EUR 48.50 target underlines the debate now facing investors: whether the pipeline wins and the upgraded cash-flow outlook are enough to justify the stock's re-rating, or whether the next leg has to come from hard numbers on earnings and deleveraging.
Ad
Bayer Stock: New Analysis - 13 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
